Joshua Gustine

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia

Steven P. Treon, Joshua Gustine, Kirsten Meid et al. · Journal of Clinical Oncology · 2018 · 177 citations · Full text

Medicine, Hematology, Pharmacology +9

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia

Steven P. Treon, Kirsten Meid, Joshua Gustine et al. · Journal of Clinical Oncology · 2020 · 150 citations · Full text

Pharmacy, Hematology, Pharmacotherapy +13

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia

Lian Xu, Nicholas Tsakmaklis, Guang Yang et al. · Blood · 2017 · 138 citations · Full text

Life Sciences, Genetics, Hematology +11

<i><scp>MYD</scp>88</i> wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival

Steven P. Treon, Joshua Gustine, Lian Xu et al. · British Journal of Haematology · 2017 · 105 citations · Full text

Medicine, Oncology, Pathology +17

<i>CXCR4</i> mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib

Jorge J. Castillo, Lian Xu, Joshua Gustine et al. · British Journal of Haematology · 2019 · 103 citations · Full text

Medicine, Molecular Genetics, Oncology +6